Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations
Identifieur interne : 001E99 ( Istex/Corpus ); précédent : 001E98; suivant : 001F00Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations
Auteurs : Pablo Martinez-Martin ; Martine Jeukens-Visser ; Kelly E. Lyons ; C. Rodriguez-Blazquez ; Caroline Selai ; Andrew Siderowf ; Mickie Welsh ; Werner Poewe ; Oliver Rascol ; Cristina Sampaio ; Glenn T. Stebbins ; Christopher G. Goetz ; Anette SchragSource :
- Movement Disorders [ 0885-3185 ] ; 2011-11.
English descriptors
- KwdEn :
Abstract
Health‐related quality of life is an important patient‐reported outcome used in intervention trials and for monitoring the consequences of health status on physical, mental, and social domains. Parkinson's disease is a complex disorder that strongly affects patients' quality of life. Several health‐related quality of life tools have been used in Parkinson's disease. A Movement Disorder Society Task Force was commissioned to rate the psychometric quality of available health‐related quality of life scales as applied to Parkinson's disease. Following the methodology adopted by previous work of the Movement Disorder Society Task Force, a review of generic and specific health‐related quality of life scales applied in studies on Parkinson's disease was completed. Considering the scales from 3 perspectives—use in Parkinson's disease, use by multiple research groups, and clinimetric properties—a final classification as “recommended,” “suggested,” or “listed” was applied to each reviewed instrument. Four generic scales (EuroQoL, Nottingham Health Profile, 36‐Item Short‐Form Health Survey, and Sickness Impact Profile) and 5 specific scales (39‐Item Parkinson's Disease Questionnaire, Parkinson's Disease Questionnaire Short Form, Parkinson's Disease Quality of Life Questionnaire, Parkinson's Impact Scale, and Scales for Outcomes in Parkinson's Disease–Psychosocial) reached the level of “recommended.” The 39‐item Parkinson's Disease Questionnaire is the most thoroughly tested and applied questionnaire. Three other generic measures (Quality of Life Questionnaire 15D, Schedule for the Evaluation of Individual Quality of Life‐Direct Weighting, and World Health Organization Quality of Life Assessment Short Version) and the specific Parkinson's Disease Quality of Life Scale are “suggested.” With a little additional effort in completing the stipulated requirements, they could reach the “recommended” level. At present there is a wide variety of health‐related quality of life measures for application in the Parkinson's disease setting, and the task force does not recommend the development of a new scale. Selection of the most appropriate instrument for a particular objective requires consideration of the characteristics of each scale and the goals of the assessment. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23834
Links to Exploration step
ISTEX:C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations</title><author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation><mods:affiliation>Alzheimer Disease Research Unit, CIEN Foundation–Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>National Centre of Epidemiology, Carlos III Institute of Health, Av. Monforte de Lemos, 5, 28029 Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Jeukens Isser, Martine" sort="Jeukens Isser, Martine" uniqKey="Jeukens Isser M" first="Martine" last="Jeukens-Visser">Martine Jeukens-Visser</name><affiliation><mods:affiliation>Department of Rehabilitation, Academic Medical Center, Amsterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name><affiliation><mods:affiliation>University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center, Kansas City, Kansas, USA</mods:affiliation></affiliation></author><author><name sortKey="Rodriguez Lazquez, C" sort="Rodriguez Lazquez, C" uniqKey="Rodriguez Lazquez C" first="C." last="Rodriguez-Blazquez">C. Rodriguez-Blazquez</name><affiliation><mods:affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Selai, Caroline" sort="Selai, Caroline" uniqKey="Selai C" first="Caroline" last="Selai">Caroline Selai</name><affiliation><mods:affiliation>Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Siderowf, Andrew" sort="Siderowf, Andrew" uniqKey="Siderowf A" first="Andrew" last="Siderowf">Andrew Siderowf</name><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Welsh, Mickie" sort="Welsh, Mickie" uniqKey="Welsh M" first="Mickie" last="Welsh">Mickie Welsh</name><affiliation><mods:affiliation>Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation><mods:affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation><mods:affiliation>Department of Clinical Neurosciences, Royal Free Hospital, University College London, London, United Kingdom</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23834</idno><idno type="url">https://api.istex.fr/document/C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001E99</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001E99</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations</title><author><name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name><affiliation><mods:affiliation>Alzheimer Disease Research Unit, CIEN Foundation–Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation><affiliation><mods:affiliation>National Centre of Epidemiology, Carlos III Institute of Health, Av. Monforte de Lemos, 5, 28029 Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Jeukens Isser, Martine" sort="Jeukens Isser, Martine" uniqKey="Jeukens Isser M" first="Martine" last="Jeukens-Visser">Martine Jeukens-Visser</name><affiliation><mods:affiliation>Department of Rehabilitation, Academic Medical Center, Amsterdam, The Netherlands</mods:affiliation></affiliation></author><author><name sortKey="Lyons, Kelly E" sort="Lyons, Kelly E" uniqKey="Lyons K" first="Kelly E." last="Lyons">Kelly E. Lyons</name><affiliation><mods:affiliation>University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center, Kansas City, Kansas, USA</mods:affiliation></affiliation></author><author><name sortKey="Rodriguez Lazquez, C" sort="Rodriguez Lazquez, C" uniqKey="Rodriguez Lazquez C" first="C." last="Rodriguez-Blazquez">C. Rodriguez-Blazquez</name><affiliation><mods:affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</mods:affiliation></affiliation></author><author><name sortKey="Selai, Caroline" sort="Selai, Caroline" uniqKey="Selai C" first="Caroline" last="Selai">Caroline Selai</name><affiliation><mods:affiliation>Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</mods:affiliation></affiliation></author><author><name sortKey="Siderowf, Andrew" sort="Siderowf, Andrew" uniqKey="Siderowf A" first="Andrew" last="Siderowf">Andrew Siderowf</name><affiliation><mods:affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</mods:affiliation></affiliation></author><author><name sortKey="Welsh, Mickie" sort="Welsh, Mickie" uniqKey="Welsh M" first="Mickie" last="Welsh">Mickie Welsh</name><affiliation><mods:affiliation>Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California, Los Angeles, California, USA</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Oliver Rascol</name><affiliation><mods:affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Sampaio, Cristina" sort="Sampaio, Cristina" uniqKey="Sampaio C" first="Cristina" last="Sampaio">Cristina Sampaio</name><affiliation><mods:affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</mods:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation><mods:affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</mods:affiliation></affiliation></author><author><name sortKey="Schrag, Anette" sort="Schrag, Anette" uniqKey="Schrag A" first="Anette" last="Schrag">Anette Schrag</name><affiliation><mods:affiliation>Department of Clinical Neurosciences, Royal Free Hospital, University College London, London, United Kingdom</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-11">2011-11</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="2371">2371</biblScope><biblScope unit="page" to="2380">2380</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942</idno><idno type="DOI">10.1002/mds.23834</idno><idno type="ArticleID">MDS23834</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>assessment</term><term>health‐related quality of life</term><term>measures</term><term>patient‐reported outcomes</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Health‐related quality of life is an important patient‐reported outcome used in intervention trials and for monitoring the consequences of health status on physical, mental, and social domains. Parkinson's disease is a complex disorder that strongly affects patients' quality of life. Several health‐related quality of life tools have been used in Parkinson's disease. A Movement Disorder Society Task Force was commissioned to rate the psychometric quality of available health‐related quality of life scales as applied to Parkinson's disease. Following the methodology adopted by previous work of the Movement Disorder Society Task Force, a review of generic and specific health‐related quality of life scales applied in studies on Parkinson's disease was completed. Considering the scales from 3 perspectives—use in Parkinson's disease, use by multiple research groups, and clinimetric properties—a final classification as “recommended,” “suggested,” or “listed” was applied to each reviewed instrument. Four generic scales (EuroQoL, Nottingham Health Profile, 36‐Item Short‐Form Health Survey, and Sickness Impact Profile) and 5 specific scales (39‐Item Parkinson's Disease Questionnaire, Parkinson's Disease Questionnaire Short Form, Parkinson's Disease Quality of Life Questionnaire, Parkinson's Impact Scale, and Scales for Outcomes in Parkinson's Disease–Psychosocial) reached the level of “recommended.” The 39‐item Parkinson's Disease Questionnaire is the most thoroughly tested and applied questionnaire. Three other generic measures (Quality of Life Questionnaire 15D, Schedule for the Evaluation of Individual Quality of Life‐Direct Weighting, and World Health Organization Quality of Life Assessment Short Version) and the specific Parkinson's Disease Quality of Life Scale are “suggested.” With a little additional effort in completing the stipulated requirements, they could reach the “recommended” level. At present there is a wide variety of health‐related quality of life measures for application in the Parkinson's disease setting, and the task force does not recommend the development of a new scale. Selection of the most appropriate instrument for a particular objective requires consideration of the characteristics of each scale and the goals of the assessment. © 2011 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Pablo Martinez‐Martin MD, PhD</name><affiliations><json:string>Alzheimer Disease Research Unit, CIEN Foundation–Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health, Madrid, Spain</json:string><json:string>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</json:string><json:string>National Centre of Epidemiology, Carlos III Institute of Health, Av. Monforte de Lemos, 5, 28029 Madrid, Spain</json:string></affiliations></json:item><json:item><name>Martine Jeukens‐Visser PhD</name><affiliations><json:string>Department of Rehabilitation, Academic Medical Center, Amsterdam, The Netherlands</json:string></affiliations></json:item><json:item><name>Kelly E. Lyons PhD</name><affiliations><json:string>University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center, Kansas City, Kansas, USA</json:string></affiliations></json:item><json:item><name>C. Rodriguez‐Blazquez BS</name><affiliations><json:string>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</json:string></affiliations></json:item><json:item><name>Caroline Selai PhD</name><affiliations><json:string>Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</json:string></affiliations></json:item><json:item><name>Andrew Siderowf MD</name><affiliations><json:string>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</json:string></affiliations></json:item><json:item><name>Mickie Welsh RN, DNSC</name><affiliations><json:string>Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California, Los Angeles, California, USA</json:string></affiliations></json:item><json:item><name>Werner Poewe MD</name><affiliations><json:string>Department of Neurology, University Hospital, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Oliver Rascol MD</name><affiliations><json:string>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</json:string></affiliations></json:item><json:item><name>Cristina Sampaio MD, PhD</name><affiliations><json:string>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</json:string></affiliations></json:item><json:item><name>Glenn T. Stebbins MD</name><affiliations><json:string>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Christopher G. Goetz MD</name><affiliations><json:string>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</json:string></affiliations></json:item><json:item><name>Anette Schrag FRCP, PhD</name><affiliations><json:string>Department of Clinical Neurosciences, Royal Free Hospital, University College London, London, United Kingdom</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>health‐related quality of life</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>measures</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>assessment</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>patient‐reported outcomes</value></json:item></subject><articleId><json:string>MDS23834</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Health‐related quality of life is an important patient‐reported outcome used in intervention trials and for monitoring the consequences of health status on physical, mental, and social domains. Parkinson's disease is a complex disorder that strongly affects patients' quality of life. Several health‐related quality of life tools have been used in Parkinson's disease. A Movement Disorder Society Task Force was commissioned to rate the psychometric quality of available health‐related quality of life scales as applied to Parkinson's disease. Following the methodology adopted by previous work of the Movement Disorder Society Task Force, a review of generic and specific health‐related quality of life scales applied in studies on Parkinson's disease was completed. Considering the scales from 3 perspectives—use in Parkinson's disease, use by multiple research groups, and clinimetric properties—a final classification as “recommended,” “suggested,” or “listed” was applied to each reviewed instrument. Four generic scales (EuroQoL, Nottingham Health Profile, 36‐Item Short‐Form Health Survey, and Sickness Impact Profile) and 5 specific scales (39‐Item Parkinson's Disease Questionnaire, Parkinson's Disease Questionnaire Short Form, Parkinson's Disease Quality of Life Questionnaire, Parkinson's Impact Scale, and Scales for Outcomes in Parkinson's Disease–Psychosocial) reached the level of “recommended.” The 39‐item Parkinson's Disease Questionnaire is the most thoroughly tested and applied questionnaire. Three other generic measures (Quality of Life Questionnaire 15D, Schedule for the Evaluation of Individual Quality of Life‐Direct Weighting, and World Health Organization Quality of Life Assessment Short Version) and the specific Parkinson's Disease Quality of Life Scale are “suggested.” With a little additional effort in completing the stipulated requirements, they could reach the “recommended” level. At present there is a wide variety of health‐related quality of life measures for application in the Parkinson's disease setting, and the task force does not recommend the development of a new scale. Selection of the most appropriate instrument for a particular objective requires consideration of the characteristics of each scale and the goals of the assessment. © 2011 Movement Disorder Society</abstract><qualityIndicators><score>8</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>2318</abstractCharCount><pdfWordCount>7202</pdfWordCount><pdfCharCount>48070</pdfCharCount><pdfPageCount>10</pdfPageCount><abstractWordCount>320</abstractWordCount></qualityIndicators><title>Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations</title><refBibs><json:item><author><json:item><name>C Acquadro</name></json:item><json:item><name>R Berzon</name></json:item><json:item><name>D Dubois</name></json:item></author><host><volume>6</volume><pages><last>531</last><first>522</first></pages><author></author><title>Value Health.</title></host><title>Incorporating the patient's perspective into drug development and communication: an Ad Hoc Task Force Report of the Patient‐Reported Outcomes (PRO) Harmonization Group Meeting at the Food and Drug Administration, February 16, 2001</title></json:item><json:item><author><json:item><name>SCA Fraser</name></json:item><json:item><name>AJ Ramirez</name></json:item><json:item><name>SR Ebbs</name></json:item></author><host><volume>67</volume><pages><last>346</last><first>341</first></pages><author></author><title>Br J Cancer.</title></host><title>A daily diary card for quality of life measurement in advanced breast cancer trials</title></json:item><json:item><host><author></author><title>Bowling A.Measuring Disease: A Review of Disease‐Specific Quality of Life Measurement Scales.Open University Press;1995.</title></host></json:item><json:item><author><json:item><name>BL Den Oudsten</name></json:item><json:item><name>GL Van Heck</name></json:item><json:item><name>J De Vries</name></json:item></author><host><volume>22</volume><pages><last>1537</last><first>1528</first></pages><author></author><title>Mov Disord.</title></host><title>Quality of Life and Related Concepts in Parkinson's Disease: A Systematic Review</title></json:item><json:item><author><json:item><name> </name></json:item></author><host><volume>18</volume><pages><last>750</last><first>738</first></pages><author></author><title>Mov Disord.</title></host><title>The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations</title></json:item><json:item><author><json:item><name>A Schrag</name></json:item><json:item><name>P Barone</name></json:item><json:item><name>RG Brown</name></json:item></author><host><volume>22</volume><pages><last>1092</last><first>1077</first></pages><author></author><title>Mov Disord.</title></host><title>Depression rating scales in Parkinson's disease: critique and recommendations</title></json:item><json:item><author><json:item><name>HH Fernandez</name></json:item><json:item><name>D Aarsland</name></json:item><json:item><name>G Fenelon</name></json:item></author><host><volume>23</volume><pages><last>500</last><first>484</first></pages><author></author><title>Mov Disord.</title></host><title>Scales to assess psychosis in Parkinson's disease: critique and recommendations</title></json:item><json:item><author><json:item><name>AFG Leentjens</name></json:item><json:item><name>K Dujardin</name></json:item><json:item><name>L Marsh</name></json:item></author><host><volume>23</volume><pages><last>2014</last><first>2004</first></pages><author></author><title>Mov Disord.</title></host><title>Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations</title></json:item><json:item><author><json:item><name>AFG Leentjens</name></json:item><json:item><name>K Dujardin</name></json:item><json:item><name>L Marsh</name></json:item></author><host><volume>23</volume><pages><last>2023</last><first>2015</first></pages><author></author><title>Mov Disord.</title></host><title>Anxiety rating scales in Parkinson's disease: critique and recommendations</title></json:item><json:item><author><json:item><name>JH Friedman</name></json:item><json:item><name>G Alves</name></json:item><json:item><name>P Hagell</name></json:item></author><host><volume>25</volume><pages><last>822</last><first>805</first></pages><author></author><title>Mov Disord.</title></host><title>Fatigue rating scales critique and recommendations by the Movement Disorders Society Task Force on Rating Scales for Parkinson's Disease</title></json:item><json:item><author><json:item><name>C Colosimo</name></json:item><json:item><name>P Martínez‐Martín</name></json:item><json:item><name>G Fabbrini</name></json:item></author><host><volume>25</volume><pages><last>1142</last><first>1131</first></pages><author></author><title>Mov Disord.</title></host><title>Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations</title></json:item><json:item><author><json:item><name>CG Goetz</name></json:item><json:item><name>BC Tilley</name></json:item><json:item><name>SR Shaftman</name></json:item></author><host><volume>23</volume><pages><last>2170</last><first>2129</first></pages><author></author><title>Mov Disord.</title></host><title>Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): scale presentation and clinimetric testing results</title></json:item><json:item><author><json:item><name>B Bergner</name></json:item><json:item><name>R Bobbitt</name></json:item><json:item><name>W Carter</name></json:item><json:item><name>B Gilson</name></json:item></author><host><volume>19</volume><pages><last>805</last><first>787</first></pages><author></author><title>Med Care.</title></host><title>The sickness impact profile: development and final revision of a health status measure</title></json:item><json:item><author><json:item><name>WT Longstreth</name></json:item><json:item><name>L Nelson</name></json:item><json:item><name>M Linde</name></json:item><json:item><name>D Munoz</name></json:item></author><host><volume>5</volume><pages><last>148</last><first>142</first></pages><author></author><title>J Geriatr Psychiatry Neurol.</title></host><title>Utility of the sickness impact profile in Parkinson's disease</title></json:item><json:item><author><json:item><name>M Welsh</name></json:item><json:item><name>E Dorflinger</name></json:item><json:item><name>D Chernik</name></json:item><json:item><name>C Waters</name></json:item></author><host><volume>15</volume><pages><last>502</last><first>497</first></pages><author></author><title>Mov Disord.</title></host><title>Illness impact and adjustment to Parkinson's disease: before and after treatment with tolcapone</title></json:item><json:item><author><json:item><name>SM Hunt</name></json:item><json:item><name>J McEwen</name></json:item><json:item><name>SP McKenna</name></json:item></author><host><volume>35</volume><pages><last>188</last><first>185</first></pages><author></author><title>J R Coll Gen Pract.</title></host><title>Measuring health status: a new tool for clinicians and epidemiologists</title></json:item><json:item><author><json:item><name>SM Hunt</name></json:item><json:item><name>SP McKenna</name></json:item><json:item><name>J McEwen</name></json:item><json:item><name>J Williams</name></json:item><json:item><name>E Papp</name></json:item></author><host><volume>15</volume><pages><last>229</last><first>221</first></pages><author></author><title>Soc Sci Med A.</title></host><title>The Nottingham Health Profile: subjective health status and medical consultations</title></json:item><json:item><author><json:item><name>SM Hunt</name></json:item><json:item><name>SP McKenna</name></json:item><json:item><name>J McEwen</name></json:item><json:item><name>EM Backett</name></json:item><json:item><name>J Williams</name></json:item><json:item><name>E Papp</name></json:item></author><host><volume>34</volume><pages><last>286</last><first>281</first></pages><author></author><title>J Epi Com Health.</title></host><title>A quantitative approach to perceived health status: a validation study</title></json:item><json:item><author><json:item><name>C Wann‐Hansson</name></json:item><json:item><name>R Klevsgard</name></json:item><json:item><name>P Hagell</name></json:item></author><host><volume>6</volume><pages><last>60</last><first>47</first></pages><author></author><title>Health Qual Life Outcomes.</title></host><title>Cross‐diagnostic validity of the Nottingham health profile index of distress (NHPD)</title></json:item><json:item><author><json:item><name>P Hagell</name></json:item><json:item><name>RE Whalley</name></json:item><json:item><name>SP McKenna</name></json:item><json:item><name>O Lindvall</name></json:item></author><host><volume>18</volume><pages><last>783</last><first>773</first></pages><author></author><title>Mov Disord.</title></host><title>Health status measurement in Parkinson's disease: Validity of the PDQ‐39 and Nottingham Health Profile</title></json:item><json:item><author><json:item><name>GM Hariz</name></json:item><json:item><name>M Lindberg</name></json:item><json:item><name>MI Hariz</name></json:item><json:item><name>AT Bergenheim</name></json:item></author><host><volume>108</volume><pages><last>37</last><first>28</first></pages><author></author><title>Acta Neurol Scand.</title></host><title>Gender differences in disability and health‐related quality of life in patients with Parkinson's disease treated with stereotactic surgery</title></json:item><json:item><author><json:item><name>T Erola</name></json:item><json:item><name>P Karinen</name></json:item><json:item><name>E Heikkinen</name></json:item></author><host><volume>11</volume><pages><last>94</last><first>89</first></pages><author></author><title>Parkinsonism Related Disord.</title></host><title>Bilateral subthalamic nucleus stimulation improves health‐related quality of life in Parkinsonian patients</title></json:item><json:item><author><json:item><name>KH Karlsen</name></json:item><json:item><name>E Tandberg</name></json:item><json:item><name>D Aarsland</name></json:item><json:item><name>JP Larsen</name></json:item></author><host><volume>69</volume><pages><last>589</last><first>584</first></pages><author></author><title>J Neurol Neurosurg Psychiatry.</title></host><title>Health related quality of life in Parkinson's disease: a prospective longitudinal study</title></json:item><json:item><author><json:item><name>EB Forsaa</name></json:item><json:item><name>JP Larsen</name></json:item><json:item><name>T Wentzel‐Larsen</name></json:item><json:item><name>K Herlofson</name></json:item><json:item><name>G Alves</name></json:item></author><host><volume>23</volume><pages><last>1427</last><first>1420</first></pages><author></author><title>Mov Disord.</title></host><title>Predictors and course of health‐related quality of life in Parkinson's disease</title></json:item><json:item><author><json:item><name> </name></json:item></author><host><volume>16</volume><pages><last>208</last><first>199</first></pages><author></author><title>Health Policy.</title></host><title>EuroQol—a new facility for the measurement of health related quality of life</title></json:item><json:item><author><json:item><name>A Siderowf</name></json:item><json:item><name>B Ravina</name></json:item><json:item><name>HA Glick</name></json:item></author><host><volume>59</volume><pages><last>108</last><first>103</first></pages><author></author><title>Neurology.</title></host><title>Preference‐based quality‐of‐life in patients with Parkinson's disease</title></json:item><json:item><author><json:item><name>A Schrag</name></json:item><json:item><name>N Quinn</name></json:item><json:item><name>M Jahanshahi</name></json:item><json:item><name>C Selai</name></json:item></author><host><volume>69</volume><pages><last>73</last><first>67</first></pages><author></author><title>J Neurol Neurosurg Psychiatry.</title></host><title>The EQ‐5D–a generic quality of life measure–is a useful instrument to measure quality of life in patients with Parkinson's disease</title></json:item><json:item><author><json:item><name>P Martínez‐Martín</name></json:item><json:item><name>J Benito‐León</name></json:item><json:item><name>F Alonso</name></json:item><json:item><name>MJ Catalán</name></json:item><json:item><name>M Pondal</name></json:item><json:item><name>I Zamarbide</name></json:item></author><host><volume>19</volume><pages><last>318</last><first>312</first></pages><author></author><title>Mov Disord.</title></host><title>Health‐related quality of life evaluation by proxy in Parkinson's disease: Approach using PDQ‐8 and EuroQoL‐5D</title></json:item><json:item><author><json:item><name>K Noyes</name></json:item><json:item><name>AW Dick</name></json:item><json:item><name>RG Holloway</name></json:item><json:item><name> </name></json:item></author><host><volume>9</volume><pages><last>38</last><first>28</first></pages><author></author><title>Value Health.</title></host><title>Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease‐specific quality of life</title></json:item><json:item><author><json:item><name>M Reuther</name></json:item><json:item><name>EA Spottke</name></json:item><json:item><name>J Klotsche</name></json:item></author><host><volume>13</volume><pages><last>114</last><first>108</first></pages><author></author><title>Parkinsonism Relat Disord.</title></host><title>Assessing health‐related quality of life in patients with Parkinson's disease in a prospective longitudinal study</title></json:item><json:item><author><json:item><name>P Martinez‐Martin</name></json:item><json:item><name>G Deuschl</name></json:item></author><host><volume>22</volume><pages><last>765</last><first>757</first></pages><author></author><title>Mov Disord.</title></host><title>Effect of medical and surgical interventions on health‐related quality of life in Parkinson's disease</title></json:item><json:item><author><json:item><name>P Martinez‐Martin</name></json:item><json:item><name>M Kurtis</name></json:item></author><host><volume>15</volume><pages><last>64</last><first>58</first></pages><issue>Suppl 4</issue><author></author><title>Parkinsonism Relat Disord.</title></host><title>Systematic review of the effect of dopamine receptor agonists on patient health‐related quality of life</title></json:item><json:item><author><json:item><name>JE Ware</name></json:item><json:item><name>CD Sherbourne</name></json:item></author><host><volume>30</volume><pages><last>483</last><first>473</first></pages><author></author><title>Med Care.</title></host><title>The MOS 36‐Item Short‐Form Health Survey (SF‐36): I. conceptual framework and item selection</title></json:item><json:item><author><json:item><name>C Jenkinson</name></json:item><json:item><name>V Peto</name></json:item><json:item><name>R Fitzpatrick</name></json:item><json:item><name>R Greenhall</name></json:item><json:item><name>N Hyman</name></json:item></author><host><volume>24</volume><pages><last>509</last><first>505</first></pages><author></author><title>Age Ageing.</title></host><title>Self‐reported functioning and well‐being in patients with Parkinson's disease: comparison of the short‐form health survey (SF‐36) and the Parkinson's Disease Questionnaire (PDQ‐39)</title></json:item><json:item><author><json:item><name>P Hobson</name></json:item><json:item><name>J Meara</name></json:item></author><host><volume>25</volume><pages><last>335</last><first>334</first></pages><author></author><title>Age Ageing.</title></host><title>Self‐reported functioning and well‐being in patients with Parkinson's disease: comparison of the short‐form 36 and the Parkinson's disease questionnaire</title></json:item><json:item><author><json:item><name>LM Rubenstein</name></json:item><json:item><name>MD Voelker</name></json:item><json:item><name>EA Chrischilles</name></json:item><json:item><name>DC Glenn</name></json:item><json:item><name>RB Wallace</name></json:item><json:item><name>RL Rodnitzky</name></json:item></author><host><volume>7</volume><pages><last>290</last><first>279</first></pages><author></author><title>Qual Life Res.</title></host><title>The Usefulness of the functional status questionnaire and medical outcomes study short form in Parkinson's disease research</title></json:item><json:item><author><json:item><name>AM Kuopio</name></json:item><json:item><name>RJ Martilla</name></json:item><json:item><name>H Helenius</name></json:item><json:item><name>M Toivonen</name></json:item><json:item><name>UK Rinne</name></json:item></author><host><volume>15</volume><pages><last>223</last><first>216</first></pages><author></author><title>Mov Disord.</title></host><title>The Quality of life in Parkinson's disease</title></json:item><json:item><author><json:item><name>T Steffen</name></json:item><json:item><name>M Seney</name></json:item></author><host><volume>88</volume><pages><last>746</last><first>733</first></pages><author></author><title>Phys Ther.</title></host><title>Test‐retest reliability and minimal detectable change on balance and ambulation tests, the 36‐item short‐form health survey, and the Unified Parkinson Disease Rating Scale in people with parkinsonism</title></json:item><json:item><author><json:item><name>BL Den Oudsten</name></json:item><json:item><name>GL Van Heck</name></json:item><json:item><name>J de Vries</name></json:item></author><host><volume>22</volume><pages><last>1401</last><first>1390</first></pages><author></author><title>Mov Disord.</title></host><title>The suitability of patient‐based measures in the field of Parkinson's disease: a systematic review</title></json:item><json:item><author><json:item><name>P Hagell</name></json:item><json:item><name>AL Tornqvist</name></json:item><json:item><name>J Hobart</name></json:item></author><host><volume>255</volume><pages><last>254</last><first>246</first></pages><author></author><title>J Neurol.</title></host><title>Testing the SF‐36 in PD: implications for reporting scale data</title></json:item><json:item><author><json:item><name>EA Chrischilles</name></json:item><json:item><name>LM Rubenstein</name></json:item><json:item><name>MD Voelker</name></json:item><json:item><name>RB Wallace</name></json:item><json:item><name>RL Rodnitsky</name></json:item></author><host><volume>13</volume><pages><last>413</last><first>406</first></pages><author></author><title>Mov Disord.</title></host><title>The health burdens of Parkinson's disease</title></json:item><json:item><author><json:item><name>P Banks</name></json:item><json:item><name>C Martin</name></json:item></author><host><volume>15</volume><pages><last>463</last><first>460</first></pages><author></author><title>J Eval Clin Practice.</title></host><title>The factor structure of the SF‐36 in Parkinson's disease</title></json:item><json:item><author><json:item><name>A Schrag</name></json:item><json:item><name>A Spottke</name></json:item><json:item><name>NP Quinn</name></json:item><json:item><name>R Dodel</name></json:item></author><host><volume>24</volume><pages><last>818</last><first>813</first></pages><author></author><title>Mov Disord.</title></host><title>Comparative responsiveness of Parkinson's disease scales to change over time</title></json:item><json:item><author><json:item><name>A Siderowf</name></json:item><json:item><name>JL Jaggi</name></json:item><json:item><name>SX Xie</name></json:item><json:item><name>C Loveland‐Jones</name></json:item><json:item><name>L Leng</name></json:item><json:item><name>H Hurtig</name></json:item></author><host><volume>21</volume><pages><last>753</last><first>746</first></pages><author></author><title>Mov Disord.</title></host><title>Long‐term effects of bilateral subthalamic nucleus stimulation on health‐related quality of life in advanced Parkinson's disease</title></json:item><json:item><author><json:item><name>CA Brown</name></json:item><json:item><name>EM Cheng</name></json:item><json:item><name>RD Hays</name></json:item><json:item><name>SD Vassar</name></json:item><json:item><name>BG Vickrey</name></json:item></author><host><volume>18</volume><pages><last>1237</last><first>1219</first></pages><author></author><title>Qual Life Res.</title></host><title>SF‐36 includes less Parkinson's disease (PD)‐targeted content but is more responsive to change than two PD‐related health‐related quality of life measures</title></json:item><json:item><author><json:item><name>CA O'Boyle</name></json:item><json:item><name>H McGee</name></json:item><json:item><name>A Hickey</name></json:item><json:item><name>K O'Malley</name></json:item><json:item><name>CR Joyce</name></json:item></author><host><volume>339</volume><pages><last>1091</last><first>1088</first></pages><author></author><title>Lancet.</title></host><title>Individual quality of life in patients undergoing hip replacement</title></json:item><json:item><author><json:item><name>AM Hickey</name></json:item><json:item><name>G Bury</name></json:item><json:item><name>CA O'Boyle</name></json:item><json:item><name>F Bradley</name></json:item><json:item><name>FD O'Kelly</name></json:item><json:item><name>W Shannon</name></json:item></author><host><volume>313</volume><pages><last>33</last><first>29</first></pages><author></author><title>BMJ.</title></host><title>A new short form individual quality of life measure (SEIQoL‐DW): application in a cohort of individuals with HIV/AIDS</title></json:item><json:item><author><json:item><name>JP Browne</name></json:item><json:item><name>CA O'Boyle</name></json:item><json:item><name>HM McGee</name></json:item><json:item><name>NJ McDonald</name></json:item><json:item><name>CR Joyce</name></json:item></author><host><volume>6</volume><pages><last>309</last><first>301</first></pages><author></author><title>Qual Life Res.</title></host><title>Development of a direct weighting procedure for quality of life domains</title></json:item><json:item><author><json:item><name>MA Lee</name></json:item><json:item><name>RW Walker</name></json:item><json:item><name>AJ Hildreth</name></json:item><json:item><name>WM Prentice</name></json:item></author><host><volume>21</volume><pages><last>1934</last><first>1929</first></pages><author></author><title>Mov Disord.</title></host><title>Individualized assessment of quality of life in idiopathic Parkinson's disease</title></json:item><json:item><author><json:item><name>L Ring</name></json:item><json:item><name>AK Lindblad</name></json:item><json:item><name>P Bendtsen</name></json:item><json:item><name>E Viklund</name></json:item><json:item><name>R Jansson</name></json:item><json:item><name>B Glimelius</name></json:item></author><host><volume>15</volume><pages><last>1177</last><first>1173</first></pages><author></author><title>Qual Life Res.</title></host><title>Feasibility and validity of a computer administered version of SEIQoL‐DW</title></json:item><json:item><author><json:item><name>P Moons</name></json:item><json:item><name>K Marquet</name></json:item><json:item><name>W Budts</name></json:item><json:item><name>S De Geest</name></json:item></author><host><volume>2</volume><pages><first>27</first></pages><author></author><title>Health Qual Life Outcomes.</title></host><title>Validity, reliability and responsiveness of the “Schedule for the Evaluation of Individual Quality of Life‐Direct Weighting” (SEIQoL‐DW) in congenital heart disease</title></json:item><json:item><author><json:item><name>C Neudert</name></json:item><json:item><name>M Wasner</name></json:item><json:item><name>GD Borasio</name></json:item></author><host><volume>191</volume><pages><last>109</last><first>103</first></pages><author></author><title>J Neurol Sci.</title></host><title>Patients' assessment of quality of life instruments: a randomised study of SIP, SF‐36 and SEIQoL‐DW in patients with amyotrophic lateral sclerosis</title></json:item><json:item><author><json:item><name>RF Coen</name></json:item><json:item><name>D O'Mahony</name></json:item><json:item><name>CA O'Boyle</name></json:item></author><host><volume>14</volume><pages><last>163</last><first>154</first></pages><author></author><title>Irish J Psychology.</title></host><title>Measuring the quality of life in dementia patients using the Schedule for the Evaluation of Individual Quality of Life</title></json:item><json:item><host><author></author><title>Sintonen H.The 15D‐measure of health‐related quality of life. I. Reliability, validity, and sensitivity of its health state descriptive system. Working paper 41.Melbourne:National Centre for Health Program Evaluation,1994.</title></host></json:item><json:item><host><author></author><title>Sintonen H.The 15D‐measure of health‐related quality of life. II. Feasibility, reliability and validity of its valuation system. Working paper 42.Melbourne, Australia:National Centre for Health Program Evaluation;1995.</title></host></json:item><json:item><author><json:item><name>H Sintonen</name></json:item></author><host><volume>33</volume><pages><last>336</last><first>328</first></pages><author></author><title>Ann Med</title></host><title>The 15D instrument of health‐related quality of life: properties and applications</title></json:item><json:item><author><json:item><name>TH Haapaniemi</name></json:item><json:item><name>DA Sotaniemi</name></json:item><json:item><name>H Sintonen</name></json:item><json:item><name>E Taimela</name></json:item></author><host><volume>75</volume><pages><last>983</last><first>976</first></pages><author></author><title>J Neurol Neurosurg Psychiatry.</title></host><title>The generic 15D instrument is valid and feasible for measuring health related quality of life in Parkinson's disease</title></json:item><json:item><author><json:item><name> </name></json:item></author><host><volume>46</volume><pages><last>1585</last><first>1569</first></pages><author></author><title>Soc Sci Med.</title></host><title>The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties</title></json:item><json:item><author><json:item><name>SM Skevington</name></json:item><json:item><name>M Lotfy</name></json:item><json:item><name>KA OConnell</name></json:item></author><host><volume>13</volume><pages><last>310</last><first>299</first></pages><author></author><title>Qual Life Res.</title></host><title>The World Health Organization's WHOQOL‐BREF quality of life assessment: psychometric properties and results of the international field trial: A report from the WHOQOL Group</title></json:item><json:item><author><json:item><name>S Saxena</name></json:item><json:item><name>D Carlson</name></json:item><json:item><name>R Billington</name></json:item></author><host><volume>10</volume><pages><last>721</last><first>711</first></pages><author></author><title>Qual Life Res.</title></host><title>The WHO quality of life assessment instrument (WHOQOL‐Bref): the importance of its items for cross‐cultural research</title></json:item><json:item><author><json:item><name>P Schestatsky</name></json:item><json:item><name>VC Zanatto</name></json:item><json:item><name>R Margis</name></json:item></author><host><volume>28</volume><pages><last>211</last><first>209</first></pages><author></author><title>Rev Bras Psiquiatr.</title></host><title>Quality of life in a Brazilian sample of patients with Parkinson's disease and their caregivers</title></json:item><json:item><author><json:item><name>MS Hirayama</name></json:item><json:item><name>S Gobbi</name></json:item><json:item><name>LT Gobbi</name></json:item><json:item><name>F Stella</name></json:item></author><host><volume>46</volume><pages><last>604</last><first>147</first></pages><author></author><title>Arch Gerontol Geriatr.</title></host><title>Quality of life (QoL) in relation to disease severity in Brazilian Parkinson's patients as measured using the WHOQOL‐BREF</title></json:item><json:item><author><json:item><name>G Henrich</name></json:item><json:item><name>P Herschbach</name></json:item></author><host><volume>16</volume><pages><last>159</last><first>150</first></pages><author></author><title>Eur J Psychol Assess.</title></host><title>Questions on life satisfaction (FLZM)—a short questionnaire for assessing subjective quality of life</title></json:item><json:item><author><json:item><name>A Kuehler</name></json:item><json:item><name>G Henrich</name></json:item><json:item><name>U Schroeder</name></json:item><json:item><name>B Conrad</name></json:item><json:item><name>P Herschbach</name></json:item><json:item><name>A Ceballos‐Baumann</name></json:item></author><host><volume>74</volume><pages><last>1030</last><first>1023</first></pages><author></author><title>J Neurol Neurosurg Psychiatry.</title></host><title>A novel quality of life instrument for deep brain stimulation in movement disorders</title></json:item><json:item><author><json:item><name>H Ellgring</name></json:item><json:item><name>S Seiler</name></json:item><json:item><name>B Perleth</name></json:item><json:item><name>W Frings</name></json:item><json:item><name>T Gasser</name></json:item><json:item><name>W Oertel</name></json:item></author><host><volume>43</volume><pages><last>44</last><first>41</first></pages><issue>Suppl</issue><author></author><title>Neurology.</title></host><title>Psychosocial aspects of Parkinson's disease</title></json:item><json:item><author><json:item><name>NG Spliethoff‐Kamminga</name></json:item><json:item><name>AH Zwinderman</name></json:item><json:item><name>MP Springer</name></json:item><json:item><name>RA Roos</name></json:item></author><host><volume>18</volume><pages><last>509</last><first>503</first></pages><author></author><title>Mov Disord.</title></host><title>Psychosocial problems in Parkinson's disease: evaluation of a disease‐specific questionnaire</title></json:item><json:item><host><author></author><title>Difference in quality of life and psychosocial well‐being between Parkinson disease patient members and non‐members of the Dutch Parkinson Disease Association</title></host></json:item><json:item><author><json:item><name>V Peto</name></json:item><json:item><name>C Jenkinson</name></json:item><json:item><name>R Fitzpatrick</name></json:item><json:item><name>R Greenhall</name></json:item></author><host><volume>4</volume><pages><last>248</last><first>241</first></pages><author></author><title>Qual Life Res.</title></host><title>The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease</title></json:item><json:item><author><json:item><name>C Jenkinson</name></json:item><json:item><name>R Fitzpatrick</name></json:item><json:item><name>V Peto</name></json:item><json:item><name>R Greenhall</name></json:item><json:item><name>N Hyman</name></json:item></author><host><volume>26</volume><pages><last>357</last><first>353</first></pages><author></author><title>Age Ageing.</title></host><title>The Parkinson's Disease Questionnaire (PDQ‐39): development and validation of a Parkinson's disease summary index score</title></json:item><json:item><author><json:item><name>FJ Carod‐Artal</name></json:item><json:item><name>P Martinez‐Martin</name></json:item><json:item><name>AP Vargas</name></json:item></author><host><volume>22</volume><pages><last>98</last><first>91</first></pages><author></author><title>Mov Disord.</title></host><title>Independent validation of SCOPA‐psychosocial and metric properties of the PDQ‐39 Brazilian version</title></json:item><json:item><author><json:item><name>C Jenkinson</name></json:item><json:item><name>R Fitzpatrick</name></json:item><json:item><name>J Norquist</name></json:item><json:item><name>L Findley</name></json:item><json:item><name>K Hughes</name></json:item></author><host><volume>56</volume><pages><last>847</last><first>843</first></pages><author></author><title>J Clin Epidemiol.</title></host><title>Cross‐cultural evaluation of the Parkinson's Disease Questionnaire: tests of data quality, score reliability, response rate, and scaling assumptions in the United States, Canada, Japan, Italy, and Spain</title></json:item><json:item><author><json:item><name>N Luo</name></json:item><json:item><name>LC Tan</name></json:item><json:item><name>SC Li</name></json:item><json:item><name>LK Soh</name></json:item><json:item><name>J Thumboo</name></json:item></author><host><volume>14</volume><pages><last>279</last><first>273</first></pages><author></author><title>Qual Life Res.</title></host><title>Validity and reliability of the Chinese (Singapore) version of the Parkinson's Disease Questionnaire (PDQ‐39)</title></json:item><json:item><author><json:item><name>P Martinez‐Martin</name></json:item><json:item><name>M Serrano‐Duenas</name></json:item><json:item><name>V Vaca‐Baquero</name></json:item></author><host><volume>11</volume><pages><last>304</last><first>297</first></pages><author></author><title>Parkinsonism Relat Disord.</title></host><title>Psychometric characteristics of the Parkinson's disease questionnaire (PDQ‐39)—Ecuadorian version</title></json:item><json:item><author><json:item><name>J Marinus</name></json:item><json:item><name>C Ramaker</name></json:item><json:item><name>JJ van Hilten</name></json:item><json:item><name>AM Stiggelbout</name></json:item></author><host><volume>72</volume><pages><last>248</last><first>241</first></pages><author></author><title>J Neurol Neurosurg Psychiatry.</title></host><title>Health related quality of life in Parkinson's disease: a systematic review of disease specific instruments</title></json:item><json:item><author><json:item><name>P Hagell</name></json:item><json:item><name>C Nygren</name></json:item></author><host><volume>78</volume><pages><last>1198</last><first>1191</first></pages><author></author><title>J Neurol Neurosurg Psychiatry.</title></host><title>The 39 item Parkinson's disease questionnaire (PDQ‐39) revisited: implications for evidence based medicine</title></json:item><json:item><author><json:item><name>P Martinez‐Martin</name></json:item><json:item><name>M Serrano‐Duenas</name></json:item><json:item><name>MJ Forjaz</name></json:item><json:item><name>MS Serrano</name></json:item></author><host><volume>16</volume><pages><last>1230</last><first>1221</first></pages><author></author><title>Qual Life Res.</title></host><title>Two questionnaires for Parkinson's disease: are the PDQ‐39 and PDQL equivalent?</title></json:item><json:item><author><json:item><name>P Hagell</name></json:item><json:item><name>SP McKenna</name></json:item></author><host><volume>10</volume><pages><last>92</last><first>89</first></pages><author></author><title>Parkinsonism Relat Disord.</title></host><title>International use of health status questionnaires in Parkinson's disease: translation is not enough</title></json:item><json:item><author><json:item><name>Z Katsarou</name></json:item><json:item><name>S Bostantjopoulou</name></json:item><json:item><name>V Peto</name></json:item><json:item><name>A Alevriadou</name></json:item><json:item><name>G Kiosseoglou</name></json:item></author><host><volume>10</volume><pages><last>163</last><first>159</first></pages><author></author><title>Qual Life Res.</title></host><title>Quality of life in Parkinson's disease: Greek translation and validation of the Parkinson's disease questionnaire (PDQ‐39)</title></json:item><json:item><author><json:item><name>V Peto</name></json:item><json:item><name>C Jenkinson</name></json:item><json:item><name>R Fitzpatrick</name></json:item></author><host><volume>30</volume><pages><last>302</last><first>299</first></pages><author></author><title>Age Ageing.</title></host><title>Determining minimally important differences for the PDQ‐39 Parkinson's disease questionnaire</title></json:item><json:item><author><json:item><name>R Fitzpatrick</name></json:item><json:item><name>JM Norquist</name></json:item><json:item><name>C Jenkinson</name></json:item></author><host><volume>57</volume><pages><last>44</last><first>40</first></pages><author></author><title>J Clin Epidemiol.</title></host><title>Distribution‐based criteria for change in health‐related quality of life in Parkinson's disease</title></json:item><json:item><author><json:item><name>C Jenkinson</name></json:item><json:item><name>R Fitzpatrick</name></json:item><json:item><name>V Peto</name></json:item><json:item><name>R Greenhall</name></json:item><json:item><name>N Hyman</name></json:item></author><host><volume>12</volume><pages><last>814</last><first>805</first></pages><author></author><title>Psychol Health.</title></host><title>The PDQ‐8: Development and validation of a short‐form Parkinson's Disease Questionnaire</title></json:item><json:item><author><json:item><name>C Jenkinson</name></json:item><json:item><name>R Fitzpatrick</name></json:item></author><host><volume>13</volume><pages><last>28</last><first>22</first></pages><author></author><title>Parkinsonism Relat Disord.</title></host><title>Cross‐cultural evaluation of the short form 8‐item Parkinson's Disease Questionnaire (PDQ‐8): results from America, Canada, Japan, Italy and Spain</title></json:item><json:item><author><json:item><name>F Franchignoni</name></json:item><json:item><name>A Giordano</name></json:item><json:item><name>G Ferriero</name></json:item></author><host><volume>17</volume><pages><last>548</last><first>541</first></pages><author></author><title>Qual Life Res.</title></host><title>Rasch analysis of the short form 8‐item Parkinson's Disease Questionnaire (PDQ‐8)</title></json:item><json:item><author><json:item><name>LC Tan</name></json:item><json:item><name>N Luo</name></json:item><json:item><name>M Nazri</name></json:item><json:item><name>SC Li</name></json:item><json:item><name>J Thumboo</name></json:item></author><host><volume>10</volume><pages><last>499</last><first>493</first></pages><author></author><title>Parkinsonism Relat Disord.</title></host><title>Validity and reliability of the PDQ‐39 and the PDQ‐8 in English‐speaking Parkinson's disease patients in Singapore</title></json:item><json:item><author><json:item><name>LC Tan</name></json:item><json:item><name>PN Lau</name></json:item><json:item><name>WL Au</name></json:item><json:item><name>N Luo</name></json:item></author><host><volume>255</volume><pages><last>80</last><first>77</first></pages><author></author><title>J Neurol Sci.</title></host><title>Validation of PDQ‐8 as an independent instrument in English and Chinese</title></json:item><json:item><author><json:item><name>Z Katsarou</name></json:item><json:item><name>S Bostantjopoulou</name></json:item><json:item><name>V Peto</name></json:item><json:item><name>A Kafantari</name></json:item><json:item><name>E Apostolidou</name></json:item><json:item><name>E Peitsidou</name></json:item></author><host><volume>19</volume><pages><last>312</last><first>308</first></pages><author></author><title>Mov Disord.</title></host><title>Assessing quality of life in Parkinson's disease: can a short‐form questionnaire be useful?</title></json:item><json:item><author><json:item><name>P Martinez‐Martin</name></json:item><json:item><name>J Benito‐Leon</name></json:item><json:item><name>F Alonso</name></json:item><json:item><name>MJ Catalan</name></json:item><json:item><name>M Pondal</name></json:item><json:item><name>I Zamarbide</name></json:item></author><host><volume>19</volume><pages><last>318</last><first>312</first></pages><author></author><title>Mov Disord.</title></host><title>Health‐related quality of life evaluation by proxy in Parkinson's disease: approach using PDQ‐8 and EuroQoL‐5D</title></json:item><json:item><author><json:item><name>KR Chaudhuri</name></json:item><json:item><name>P Martinez‐Martin</name></json:item><json:item><name>RG Brown</name></json:item></author><host><volume>22</volume><pages><last>1911</last><first>1901</first></pages><author></author><title>Mov Disord.</title></host><title>The metric properties of a novel non‐motor symptoms scale for Parkinson's disease: Results from an international pilot study</title></json:item><json:item><author><json:item><name>N Luo</name></json:item><json:item><name>LC Tan</name></json:item><json:item><name>Y Zhao</name></json:item><json:item><name>PN Lau</name></json:item><json:item><name>WL Au</name></json:item><json:item><name>SC Li</name></json:item></author><host><volume>24</volume><pages><last>187</last><first>183</first></pages><author></author><title>Mov Disord.</title></host><title>Determination of the longitudinal validity and minimally important difference of the 8‐item Parkinson's Disease Questionnaire (PDQ‐8)</title></json:item><json:item><author><json:item><name>S Calne</name></json:item><json:item><name>M Schulzer</name></json:item><json:item><name>E Mak</name></json:item></author><host><volume>2</volume><pages><last>61</last><first>55</first></pages><author></author><title>Parkinsonism Relat Disord.</title></host><title>Validating a quality of life Rating Scale for Idiopathic Parkinsonism: Parkinson's Impact Scale (PIMS)</title></json:item><json:item><author><json:item><name>SM Calne</name></json:item><json:item><name>E Mak</name></json:item><json:item><name>J Hall</name></json:item></author><host><volume>91</volume><pages><last>122</last><first>115</first></pages><author></author><title>Adv Neurol.</title></host><title>Validating a quality‐of‐life scale in caregivers of patients with Parkinson's disease: Parkinson's Impact Scale (PIMS)</title></json:item><json:item><author><json:item><name>M Serrano‐Duenas</name></json:item></author><host><volume>14</volume><pages><last>132</last><first>126</first></pages><author></author><title>Parkinsonism Relat Disord.</title></host><title>Serrano S. Psychometric characteristics of PIMS‐ compared to PDQ 39 and PDQL to evaluate quality of life in Parkinson's disease patients: validation in Spanish (Ecuadorian style)</title></json:item><json:item><author><json:item><name>M Schulzer</name></json:item><json:item><name>E Mak</name></json:item><json:item><name>SM Calne</name></json:item></author><host><volume>9</volume><pages><last>294</last><first>291</first></pages><author></author><title>Parkinsonism Relat Disord.</title></host><title>The psychometric properties of the Parkinson's Impact Scale (PIMS) as a measure of quality of life in Parkinson's disease</title></json:item><json:item><author><json:item><name>AG de Boer</name></json:item><json:item><name>W Wijker</name></json:item><json:item><name>JD Speelman</name></json:item><json:item><name>JC de Haes</name></json:item></author><host><volume>61</volume><pages><last>74</last><first>70</first></pages><author></author><title>J Neurol Neurosurg Psychiatry.</title></host><title>Quality of life in patients with Parkinson's disease: development of a questionnaire</title></json:item><json:item><author><json:item><name>M Serrano‐Duenas</name></json:item><json:item><name>P Martinez‐Martin</name></json:item><json:item><name>V Vaca‐Baquero</name></json:item></author><host><volume>10</volume><pages><last>437</last><first>433</first></pages><author></author><title>Parkinsonism Relat Disord.</title></host><title>Validation and cross‐cultural adjustment of PDQL‐questionnaire, Spanish version (Ecuador) (PDQL‐EV)</title></json:item><json:item><author><json:item><name>P Hobson</name></json:item><json:item><name>A Holden</name></json:item><json:item><name>J Meara</name></json:item></author><host><volume>28</volume><pages><last>346</last><first>341</first></pages><author></author><title>Age Ageing.</title></host><title>Measuring the impact of Parkinson's disease with the Parkinson's Disease Quality of Life questionnaire</title></json:item><json:item><author><json:item><name>MA de Bie</name></json:item><json:item><name>RJ de Haan</name></json:item><json:item><name>PCG Nijssen</name></json:item></author><host><volume>354</volume><pages><last>1669</last><first>1665</first></pages><author></author><title>Lancet.</title></host><title>Unilateral pallidotomy in Parkinson's disease: a randomised, single‐blind, multicentre trial</title></json:item><json:item><author><json:item><name>RA Esselink</name></json:item><json:item><name>RM de Bie</name></json:item><json:item><name>RJ de Haan</name></json:item></author><host><volume>62</volume><pages><last>207</last><first>201</first></pages><author></author><title>Neurology.</title></host><title>Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial</title></json:item><json:item><author><json:item><name>B Yousefi</name></json:item><json:item><name>V Tadibi</name></json:item><json:item><name>AF Khoei</name></json:item><json:item><name>A Montazeri</name></json:item></author><host><volume>10</volume><pages><first>67</first></pages><author></author><title>Trials</title></host><title>Exercise therapy, quality of life, and activities of daily living in patients with Parkinson disease: a small scale quasi‐randomised trial</title></json:item><json:item><author><json:item><name>M Reuther</name></json:item><json:item><name>EA Spottke</name></json:item><json:item><name>J Klotsche</name></json:item></author><host><volume>13</volume><pages><last>114</last><first>108</first></pages><author></author><title>Parkinsonism Relat Disord.</title></host><title>Assessing health‐related quality of life in patients with Parkinson's disease in a prospective longitudinal study</title></json:item><json:item><author><json:item><name>M Welsh</name></json:item><json:item><name>M McDermott</name></json:item><json:item><name>R Holloway</name></json:item></author><host><volume>12</volume><pages><first>836</first></pages><author></author><title>Mov Disord.</title></host><title>Development and testing of the Parkinson's disease quality of life scale: the PDQUALIF [abstract]</title></json:item><json:item><author><json:item><name>M Welsh</name></json:item><json:item><name>MP McDermott</name></json:item><json:item><name>RG Holloway</name></json:item></author><host><volume>18</volume><pages><last>645</last><first>637</first></pages><author></author><title>Mov Disord.</title></host><title>Devlopment and testing of the Parkinson's disease quality of life scale (PDQUALIF)</title></json:item><json:item><author><json:item><name> </name></json:item></author><host><volume>59</volume><pages><last>1943</last><first>1937</first></pages><author></author><title>Arch Neurol.</title></host><title>A controlled trial of rasagiline in early Parkinson disease. The TEMPO Study</title></json:item><json:item><author><json:item><name> </name></json:item></author><host><volume>61</volume><pages><last>1053</last><first>1044</first></pages><author></author><title>Arch Neurol.</title></host><title>Pramipexole vs Levodopa as initial treatment for Parkinson's disease</title></json:item><json:item><author><json:item><name> </name></json:item></author><host><volume>62</volume><pages><last>248</last><first>241</first></pages><author></author><title>Arch Neurol.</title></host><title>A randomized placebo‐controlled trial of rasagiline in levodopa‐treated patients with Parkinson disease and motor fluctuations. The PRESTO Study</title></json:item><json:item><author><json:item><name>M Van den Berg</name></json:item></author><host><volume>4</volume><pages><last>226</last><first>221</first></pages><author></author><title>Neurol Rehabil.</title></host><title>Leben mit Parkinson: Entwicklung und psychometrische Testung des Fragenbogens PLQ</title></json:item><json:item><author><json:item><name>M Brod</name></json:item><json:item><name>GA Mendelsohn</name></json:item><json:item><name>B Roberts</name></json:item></author><host><volume>53B</volume><pages><last>222</last><first>213</first></pages><author></author><title>J Gerontol Psych Sci.</title></host><title>Patients' experiences of Parkinson's disease</title></json:item><json:item><author><json:item><name>J Marinus</name></json:item><json:item><name>M Visser</name></json:item><json:item><name>P Martinez‐Martin</name></json:item><json:item><name>JJ van Hilten</name></json:item><json:item><name>AM Stiggelbout</name></json:item></author><host><volume>56</volume><pages><last>67</last><first>61</first></pages><author></author><title>J Clin Epidemiol.</title></host><title>A short psychosocial questionnaire for patients with Parkinson's disease: the SCOPA‐PS</title></json:item><json:item><author><json:item><name>P Martinez‐Martin</name></json:item><json:item><name>E Carroza‐García</name></json:item><json:item><name>B Frades‐Payo</name></json:item></author><host><volume>49</volume><pages><last>7</last><first>1</first></pages><author></author><title>Rev Neurol.</title></host><title>[Psychometric attributes of the Scales for Outcomes in Parkinson's Disease‐Psychosocial (SCOPA‐PS): validation in Spain and review]</title></json:item><json:item><author><json:item><name>J Virues‐Ortega</name></json:item><json:item><name>FJ Carod‐Artal</name></json:item><json:item><name>M Serrano‐Duenas</name></json:item></author><host><volume>12</volume><pages><last>391</last><first>385</first></pages><author></author><title>Value Health.</title></host><title>Cross‐cultural validation of the Scales for Outcomes in Parkinson's Disease—Psychosocial Questionnaire (SCOPA‐PS) in Four Latin American Countries</title></json:item><json:item><author><json:item><name>P Martinez‐Martin</name></json:item><json:item><name>FJ Carod‐Artal</name></json:item></author><host><volume>23</volume><pages><last>1523</last><first>1516</first></pages><author></author><title>Mov Disord.</title></host><title>Longitudinal psychometric attributes, responsiveness, and importance of change: an approach using the SCOPA‐Psychosocial Questionnaire</title></json:item><json:item><author><json:item><name>SE Soh</name></json:item><json:item><name>J McGinley</name></json:item><json:item><name>ME Morris</name></json:item></author><host><volume>97</volume><pages><last>89</last><first>83</first></pages><author></author><title>Physiotherapy.</title></host><title>Measuring quality of life in Parkinson's disease: selection of‐an‐appropriate health‐related quality of life instrument</title></json:item><json:item><author><json:item><name>LB Mokkink</name></json:item><json:item><name>CB Terwee</name></json:item><json:item><name>DL Patrick</name></json:item></author><host><volume>19</volume><pages><last>549</last><first>539</first></pages><author></author><title>Qual Life Res.</title></host><title>The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study</title></json:item><json:item><author><json:item><name>AM Damiano</name></json:item><json:item><name>C Snyder</name></json:item><json:item><name>B Strausser</name></json:item></author><host><volume>8</volume><pages><last>243</last><first>235</first></pages><author></author><title>Qual Life Res.</title></host><title>A review of health‐related quality‐of‐life concepts and measures for Parkinson's disease</title></json:item><json:item><author><json:item><name>C Selai</name></json:item><json:item><name>MR Trimble</name></json:item></author><host><volume>3</volume><pages><last>111</last><first>101</first></pages><author></author><title>Aging Mental Health.</title></host><title>Assessing quality of life in dementia</title></json:item><json:item><author><json:item><name>JL Mack</name></json:item><json:item><name>PJ Whitehouse</name></json:item></author><host><volume>15</volume><pages><last>71</last><first>69</first></pages><author></author><title>Alzheimer Dis Assoc Disord.</title></host><title>Quality of life in dementia: state of the art‐ Report of the International Working Group for Harmonization of Dementia Drug Guidelines and the Alzheimer's Society Satellite Meeting</title></json:item><json:item><author><json:item><name>S Banerjee</name></json:item><json:item><name>K Samsi</name></json:item><json:item><name>CD Petrie</name></json:item></author><host><volume>24</volume><pages><last>24</last><first>15</first></pages><author></author><title>Int J Geriatr Psychiatry.</title></host><title>What do we know about quality of life in dementia? A review of the emerging evidence on the predictive and explanatory value of disease specific measures of health related quality of life in people with dementia</title></json:item><json:item><author><json:item><name>A Vogel</name></json:item><json:item><name>EL Mortensen</name></json:item><json:item><name>SG Hasselbalch</name></json:item></author><host><volume>21</volume><pages><last>1138</last><first>1132</first></pages><author></author><title>Int J Geriatr Psychiatry.</title></host><title>Patient versus informant reported quality of life in the earliest phases of Alzheimer's disease</title></json:item><json:item><author><json:item><name>JL Conde‐Sala</name></json:item><json:item><name>J Garre‐Olmo</name></json:item><json:item><name>O Turro‐Garriga</name></json:item><json:item><name>S Lopez‐Pousa</name></json:item><json:item><name>J Vilalta‐Franch</name></json:item></author><host><volume>24</volume><pages><last>594</last><first>585</first></pages><author></author><title>Int J Geriatr Psychiatry.</title></host><title>Factors related to perceived quality of life in patients with Alzheimer's disease: the patient's perception compared with that of caregivers</title></json:item><json:item><author><json:item><name>A Schrag</name></json:item><json:item><name>M Jahansahi</name></json:item><json:item><name>NP Quinn</name></json:item></author><host><volume>69</volume><pages><last>312</last><first>308</first></pages><author></author><title>J Neurol Neurosurg Psychiatry.</title></host><title>What contributes to quality of life in patients with Parkinson's disease?</title></json:item><json:item><author><json:item><name>M Visser</name></json:item><json:item><name>SM van Rooden</name></json:item><json:item><name>D Verbaan</name></json:item><json:item><name>J Marinus</name></json:item><json:item><name>AM Stiggelbout</name></json:item><json:item><name>JJ van Hilten</name></json:item></author><host><volume>255</volume><pages><last>1587</last><first>1580</first></pages><author></author><title>J Neurol.</title></host><title>A comprehensive model of health‐related quality of life in Parkinson's disease</title></json:item><json:item><author><json:item><name>P Martinez‐Martin</name></json:item><json:item><name>C Rodriguez‐Blazquez</name></json:item><json:item><name>K Abe</name></json:item></author><host><volume>73</volume><pages><last>1591</last><first>1584</first></pages><author></author><title>Neurology.</title></host><title>International study on the psychometric attributes of the Non‐Motor Symptoms Scale in Parkinson disease</title></json:item><json:item><author><json:item><name>H Li</name></json:item><json:item><name>M Zhang</name></json:item><json:item><name>L Chen</name></json:item></author><host><volume>25</volume><pages><last>2746</last><first>2740</first></pages><author></author><title>Mov Disord.</title></host><title>Nonmotor symptoms are independently associated with impaired health‐related quality of life in Chinese patients with Parkinson's disease</title></json:item><json:item><author><json:item><name>P Martinez‐Martin</name></json:item><json:item><name>C Rodriguez‐Blazquez</name></json:item><json:item><name>MM Kurtis</name></json:item><json:item><name>K Ray Chaudhuri</name></json:item><json:item><name> </name></json:item></author><host><volume>26</volume><pages><last>406</last><first>399</first></pages><author></author><title>Mov Disord.</title></host><title>The impact of non motor symptoms on health‐related quality of life of patients with Parkinson's disease</title></json:item><json:item><author><json:item><name>P Martinez‐Martin</name></json:item><json:item><name>FJ Carod Artal</name></json:item><json:item><name>J de Pedro</name></json:item></author><host><pages><last>320</last><first>309</first></pages><author></author><title>Non‐Motor Symptoms of Parkinson's Disease</title></host><title>Non‐motor symptoms and health‐related quality of life</title></json:item><json:item><host><author></author><title>Food and Drug Administration.Guidance for Industry. Patient‐Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims.US Department of Health and Human Services,FDA;2006.</title></host></json:item><json:item><author><json:item><name>DA Gallagher</name></json:item><json:item><name>A Schrag</name></json:item></author><host><volume>22</volume><pages><last>586</last><first>563</first></pages><author></author><title>CNS Drugs.</title></host><title>Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease</title></json:item><json:item><author><json:item><name>G Deuschl</name></json:item><json:item><name>C Schade‐Brittinger</name></json:item><json:item><name>P Krack</name></json:item></author><host><volume>355</volume><pages><last>908</last><first>896</first></pages><author></author><title>N Engl J Med.</title></host><title>A randomized trial of deep‐brain stimulation for Parkinson's disease</title></json:item><json:item><author><json:item><name>J Rodrigues</name></json:item><json:item><name>SE Walters</name></json:item><json:item><name>P Watson</name></json:item><json:item><name>R Stell</name></json:item><json:item><name>FL Mastaglia</name></json:item></author><host><volume>22</volume><pages><last>1870</last><first>1866</first></pages><author></author><title>Mov Disord.</title></host><title>Globus pallidus stimulation improves both motor and nonmotor aspects of quality of life in advanced Parkinson's disease</title></json:item><json:item><author><json:item><name>LB Zahodne</name></json:item><json:item><name>MS Okun</name></json:item><json:item><name>KD Foote</name></json:item></author><host><volume>56</volume><pages><last>1329</last><first>1321</first></pages><author></author><title>J Neurol.</title></host><title>Greater improvement in quality of life following unilateral deep brain stimulation surgery in the globus pallidus as compared to the subthalamic nucleus</title></json:item><json:item><author><json:item><name>P Hagell</name></json:item><json:item><name>J Reimer</name></json:item><json:item><name>P Nyberg</name></json:item></author><host><volume>12</volume><pages><last>617</last><first>613</first></pages><author></author><title>Value Health.</title></host><title>Whose quality of life? Ethical implications in patient‐reported health outcome measurement</title></json:item></refBibs><genre><json:string>article</json:string></genre><host><volume>26</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>10</total><last>2380</last><first>2371</first></pages><issn><json:string>0885-3185</json:string></issn><issue>13</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><categories><wos><json:string>science</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix></categories><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1002/mds.23834</json:string></doi><id>C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942</id><score>0.13769238</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Copyright © 2011 Movement Disorder Society</p></availability><date>2011</date></publicationStmt><notesStmt><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations</title><author xml:id="author-1"><persName><forename type="first">Pablo</forename><surname>Martinez‐Martin</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Alzheimer Disease Research Unit, CIEN Foundation–Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health, Madrid, Spain</affiliation><affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</affiliation><affiliation>National Centre of Epidemiology, Carlos III Institute of Health, Av. Monforte de Lemos, 5, 28029 Madrid, Spain</affiliation></author><author xml:id="author-2"><persName><forename type="first">Martine</forename><surname>Jeukens‐Visser</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Rehabilitation, Academic Medical Center, Amsterdam, The Netherlands</affiliation></author><author xml:id="author-3"><persName><forename type="first">Kelly E.</forename><surname>Lyons</surname></persName><roleName type="degree">PhD</roleName><affiliation>University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center, Kansas City, Kansas, USA</affiliation></author><author xml:id="author-4"><persName><forename type="first">C.</forename><surname>Rodriguez‐Blazquez</surname></persName><roleName type="degree">BS</roleName><affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</affiliation></author><author xml:id="author-5"><persName><forename type="first">Caroline</forename><surname>Selai</surname></persName><roleName type="degree">PhD</roleName><affiliation>Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</affiliation></author><author xml:id="author-6"><persName><forename type="first">Andrew</forename><surname>Siderowf</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</affiliation></author><author xml:id="author-7"><persName><forename type="first">Mickie</forename><surname>Welsh</surname></persName><roleName type="degree">RN, DNSC</roleName><affiliation>Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California, Los Angeles, California, USA</affiliation></author><author xml:id="author-8"><persName><forename type="first">Werner</forename><surname>Poewe</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</affiliation></author><author xml:id="author-9"><persName><forename type="first">Oliver</forename><surname>Rascol</surname></persName><roleName type="degree">MD</roleName><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</affiliation></author><author xml:id="author-10"><persName><forename type="first">Cristina</forename><surname>Sampaio</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</affiliation></author><author xml:id="author-11"><persName><forename type="first">Glenn T.</forename><surname>Stebbins</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author><author xml:id="author-12"><persName><forename type="first">Christopher G.</forename><surname>Goetz</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</affiliation></author><author xml:id="author-13"><persName><forename type="first">Anette</forename><surname>Schrag</surname></persName><roleName type="degree">FRCP, PhD</roleName><affiliation>Department of Clinical Neurosciences, Royal Free Hospital, University College London, London, United Kingdom</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-11"></date><biblScope unit="volume">26</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="2371">2371</biblScope><biblScope unit="page" to="2380">2380</biblScope></imprint></monogr><idno type="istex">C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942</idno><idno type="DOI">10.1002/mds.23834</idno><idno type="ArticleID">MDS23834</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Health‐related quality of life is an important patient‐reported outcome used in intervention trials and for monitoring the consequences of health status on physical, mental, and social domains. Parkinson's disease is a complex disorder that strongly affects patients' quality of life. Several health‐related quality of life tools have been used in Parkinson's disease. A Movement Disorder Society Task Force was commissioned to rate the psychometric quality of available health‐related quality of life scales as applied to Parkinson's disease. Following the methodology adopted by previous work of the Movement Disorder Society Task Force, a review of generic and specific health‐related quality of life scales applied in studies on Parkinson's disease was completed. Considering the scales from 3 perspectives—use in Parkinson's disease, use by multiple research groups, and clinimetric properties—a final classification as “recommended,” “suggested,” or “listed” was applied to each reviewed instrument. Four generic scales (EuroQoL, Nottingham Health Profile, 36‐Item Short‐Form Health Survey, and Sickness Impact Profile) and 5 specific scales (39‐Item Parkinson's Disease Questionnaire, Parkinson's Disease Questionnaire Short Form, Parkinson's Disease Quality of Life Questionnaire, Parkinson's Impact Scale, and Scales for Outcomes in Parkinson's Disease–Psychosocial) reached the level of “recommended.” The 39‐item Parkinson's Disease Questionnaire is the most thoroughly tested and applied questionnaire. Three other generic measures (Quality of Life Questionnaire 15D, Schedule for the Evaluation of Individual Quality of Life‐Direct Weighting, and World Health Organization Quality of Life Assessment Short Version) and the specific Parkinson's Disease Quality of Life Scale are “suggested.” With a little additional effort in completing the stipulated requirements, they could reach the “recommended” level. At present there is a wide variety of health‐related quality of life measures for application in the Parkinson's disease setting, and the task force does not recommend the development of a new scale. Selection of the most appropriate instrument for a particular objective requires consideration of the characteristics of each scale and the goals of the assessment. © 2011 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>Parkinson's disease</term></item><item><term>health‐related quality of life</term></item><item><term>measures</term></item><item><term>assessment</term></item><item><term>patient‐reported outcomes</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2010-02-17">Received</change><change when="2011-05-02">Registration</change><change when="2011-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="130"><doi origin="wiley" registered="yes">10.1002/mds.v26.13</doi><numberingGroup><numbering type="journalVolume" number="26">26</numbering><numbering type="journalIssue">13</numbering></numberingGroup><coverDate startDate="2011-11">November 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="120" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23834</doi><idGroup><id type="unit" value="MDS23834"></id></idGroup><countGroup><count type="pageTotal" number="10"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2011 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2010-02-17"></event><event type="manuscriptRevised" date="2011-04-28"></event><event type="manuscriptAccepted" date="2011-05-02"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.0.1 mode:FullText" date="2011-12-13"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-07-06"></event><event type="publishedOnlineFinalForm" date="2011-11-22"></event><event type="firstOnline" date="2011-07-06"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2371</numbering><numbering type="pageLast">2380</numbering></numberingGroup><correspondenceTo>National Centre of Epidemiology, Carlos III Institute of Health, Av. Monforte de Lemos, 5, 28029 Madrid, Spain</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23834.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="131"></count><count type="wordTotal" number="10006"></count></countGroup><titleGroup><title type="main" xml:lang="en">Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations<link href="#fn1"></link><link href="#fn2"></link></title><title type="short" xml:lang="en">Health‐Related QoL Scales in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Pablo</givenNames><familyName>Martinez‐Martin</familyName><degrees>MD, PhD</degrees></personName><contactDetails><email>pmartinez@isciii.es</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Martine</givenNames><familyName>Jeukens‐Visser</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Kelly E.</givenNames><familyName>Lyons</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af2"><personName><givenNames>C.</givenNames><familyName>Rodriguez‐Blazquez</familyName><degrees>BS</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Caroline</givenNames><familyName>Selai</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af6"><personName><givenNames>Andrew</givenNames><familyName>Siderowf</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af7"><personName><givenNames>Mickie</givenNames><familyName>Welsh</familyName><degrees>RN, DNSC</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af8"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af9"><personName><givenNames>Oliver</givenNames><familyName>Rascol</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af10"><personName><givenNames>Cristina</givenNames><familyName>Sampaio</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af11"><personName><givenNames>Glenn T.</givenNames><familyName>Stebbins</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af11"><personName><givenNames>Christopher G.</givenNames><familyName>Goetz</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au13" creatorRole="author" affiliationRef="#af12"><personName><givenNames>Anette</givenNames><familyName>Schrag</familyName><degrees>FRCP, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="ES" type="organization"><unparsedAffiliation>Alzheimer Disease Research Unit, CIEN Foundation–Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health, Madrid, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="ES" type="organization"><unparsedAffiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="NL" type="organization"><unparsedAffiliation>Department of Rehabilitation, Academic Medical Center, Amsterdam, The Netherlands</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center, Kansas City, Kansas, USA</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="GB" type="organization"><unparsedAffiliation>Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</unparsedAffiliation></affiliation><affiliation xml:id="af7" countryCode="US" type="organization"><unparsedAffiliation>Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California, Los Angeles, California, USA</unparsedAffiliation></affiliation><affiliation xml:id="af8" countryCode="AT" type="organization"><unparsedAffiliation>Department of Neurology, University Hospital, Innsbruck, Austria</unparsedAffiliation></affiliation><affiliation xml:id="af9" countryCode="FR" type="organization"><unparsedAffiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af10" countryCode="PT" type="organization"><unparsedAffiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</unparsedAffiliation></affiliation><affiliation xml:id="af11" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</unparsedAffiliation></affiliation><affiliation xml:id="af12" countryCode="GB" type="organization"><unparsedAffiliation>Department of Clinical Neurosciences, Royal Free Hospital, University College London, London, United Kingdom</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">health‐related quality of life</keyword><keyword xml:id="kwd3">measures</keyword><keyword xml:id="kwd4">assessment</keyword><keyword xml:id="kwd5">patient‐reported outcomes</keyword></keywordGroup><supportingInformation><p> Additional Supporting Information may be found in the online version of this article. </p><supportingInfoItem><mediaResource alt="supporting information" href="urn-x:wiley:08853185:media:mds23834:MDS_23834_sm_suppinfo"></mediaResource><caption>Supporting Information.</caption></supportingInfoItem></supportingInformation><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Health‐related quality of life is an important patient‐reported outcome used in intervention trials and for monitoring the consequences of health status on physical, mental, and social domains. Parkinson's disease is a complex disorder that strongly affects patients' quality of life. Several health‐related quality of life tools have been used in Parkinson's disease. A Movement Disorder Society Task Force was commissioned to rate the psychometric quality of available health‐related quality of life scales as applied to Parkinson's disease. Following the methodology adopted by previous work of the Movement Disorder Society Task Force, a review of generic and specific health‐related quality of life scales applied in studies on Parkinson's disease was completed. Considering the scales from 3 perspectives—use in Parkinson's disease, use by multiple research groups, and clinimetric properties—a final classification as “recommended,” “suggested,” or “listed” was applied to each reviewed instrument. Four generic scales (EuroQoL, Nottingham Health Profile, 36‐Item Short‐Form Health Survey, and Sickness Impact Profile) and 5 specific scales (39‐Item Parkinson's Disease Questionnaire, Parkinson's Disease Questionnaire Short Form, Parkinson's Disease Quality of Life Questionnaire, Parkinson's Impact Scale, and Scales for Outcomes in Parkinson's Disease–Psychosocial) reached the level of “recommended.” The 39‐item Parkinson's Disease Questionnaire is the most thoroughly tested and applied questionnaire. Three other generic measures (Quality of Life Questionnaire 15D, Schedule for the Evaluation of Individual Quality of Life‐Direct Weighting, and World Health Organization Quality of Life Assessment Short Version) and the specific Parkinson's Disease Quality of Life Scale are “suggested.” With a little additional effort in completing the stipulated requirements, they could reach the “recommended” level. At present there is a wide variety of health‐related quality of life measures for application in the Parkinson's disease setting, and the task force does not recommend the development of a new scale. Selection of the most appropriate instrument for a particular objective requires consideration of the characteristics of each scale and the goals of the assessment. © 2011 <i>Movement</i> Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p><b>Relevant conflicts of interest/financial disclosures:</b> Nothing to report.</p></note><note xml:id="fn2"><p>Full financial disclosures and author roles may be found in the online version of this article.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Health‐Related QoL Scales in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations</title></titleInfo><name type="personal"><namePart type="given">Pablo</namePart><namePart type="family">Martinez‐Martin</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Alzheimer Disease Research Unit, CIEN Foundation–Reina Sofia Foundation, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health, Madrid, Spain</affiliation><affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</affiliation><affiliation>National Centre of Epidemiology, Carlos III Institute of Health, Av. Monforte de Lemos, 5, 28029 Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Martine</namePart><namePart type="family">Jeukens‐Visser</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Rehabilitation, Academic Medical Center, Amsterdam, The Netherlands</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kelly E.</namePart><namePart type="family">Lyons</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>University of Kansas Medical Center, Parkinson's Disease and Movement Disorder Center, Kansas City, Kansas, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Rodriguez‐Blazquez</namePart><namePart type="termsOfAddress">BS</namePart><affiliation>National Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Caroline</namePart><namePart type="family">Selai</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Sobell Department of Motor Neuroscience & Movement Disorders, University College London, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Andrew</namePart><namePart type="family">Siderowf</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mickie</namePart><namePart type="family">Welsh</namePart><namePart type="termsOfAddress">RN, DNSC</namePart><affiliation>Division of Movement Disorders, USC/Keck School of Medicine, University of Southern California, Los Angeles, California, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University Hospital, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Oliver</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Laboratoire de Pharmacologie Medicale et Clinique, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cristina</namePart><namePart type="family">Sampaio</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Laboratory of Clinical Pharmacology and Therapeutics, Lisbon School of Medicine, Lisbon, Portugal</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Glenn T.</namePart><namePart type="family">Stebbins</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christopher G.</namePart><namePart type="family">Goetz</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Services, Rush University Medical Center, Chicago, Illinois, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anette</namePart><namePart type="family">Schrag</namePart><namePart type="termsOfAddress">FRCP, PhD</namePart><affiliation>Department of Clinical Neurosciences, Royal Free Hospital, University College London, London, United Kingdom</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2011-11</dateIssued><dateCaptured encoding="w3cdtf">2010-02-17</dateCaptured><dateValid encoding="w3cdtf">2011-05-02</dateValid><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">131</extent><extent unit="words">10006</extent></physicalDescription><abstract lang="en">Health‐related quality of life is an important patient‐reported outcome used in intervention trials and for monitoring the consequences of health status on physical, mental, and social domains. Parkinson's disease is a complex disorder that strongly affects patients' quality of life. Several health‐related quality of life tools have been used in Parkinson's disease. A Movement Disorder Society Task Force was commissioned to rate the psychometric quality of available health‐related quality of life scales as applied to Parkinson's disease. Following the methodology adopted by previous work of the Movement Disorder Society Task Force, a review of generic and specific health‐related quality of life scales applied in studies on Parkinson's disease was completed. Considering the scales from 3 perspectives—use in Parkinson's disease, use by multiple research groups, and clinimetric properties—a final classification as “recommended,” “suggested,” or “listed” was applied to each reviewed instrument. Four generic scales (EuroQoL, Nottingham Health Profile, 36‐Item Short‐Form Health Survey, and Sickness Impact Profile) and 5 specific scales (39‐Item Parkinson's Disease Questionnaire, Parkinson's Disease Questionnaire Short Form, Parkinson's Disease Quality of Life Questionnaire, Parkinson's Impact Scale, and Scales for Outcomes in Parkinson's Disease–Psychosocial) reached the level of “recommended.” The 39‐item Parkinson's Disease Questionnaire is the most thoroughly tested and applied questionnaire. Three other generic measures (Quality of Life Questionnaire 15D, Schedule for the Evaluation of Individual Quality of Life‐Direct Weighting, and World Health Organization Quality of Life Assessment Short Version) and the specific Parkinson's Disease Quality of Life Scale are “suggested.” With a little additional effort in completing the stipulated requirements, they could reach the “recommended” level. At present there is a wide variety of health‐related quality of life measures for application in the Parkinson's disease setting, and the task force does not recommend the development of a new scale. Selection of the most appropriate instrument for a particular objective requires consideration of the characteristics of each scale and the goals of the assessment. © 2011 Movement Disorder Society</abstract><note type="content">*Relevant conflicts of interest/financial disclosures: Nothing to report.</note><note type="content">*Full financial disclosures and author roles may be found in the online version of this article.</note><subject lang="en"><genre>keywords</genre><topic>Parkinson's disease</topic><topic>health‐related quality of life</topic><topic>measures</topic><topic>assessment</topic><topic>patient‐reported outcomes</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="journal">journal</genre><note type="content"> Additional Supporting Information may be found in the online version of this article.Supporting Info Item: Supporting Information. - </note><subject><genre>article-category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>26</number></detail><detail type="issue"><caption>no.</caption><number>13</number></detail><extent unit="pages"><start>2371</start><end>2380</end><total>10</total></extent></part></relatedItem><identifier type="istex">C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942</identifier><identifier type="DOI">10.1002/mds.23834</identifier><identifier type="ArticleID">MDS23834</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2011 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E99 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001E99 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:C01E2DAFFA05A560AE15850ABA73BB5C7BBF6942
|texte= Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations
}}
| This area was generated with Dilib version V0.6.29. |  |